Search
인용 및 참조 문헌 (6)
Gibco™
Opti-MEM™ Reduced Serum Medium, powder
Opti-MEM™ Reduced-Serum Medium is an improved Minimal Essential Medium (MEM) that allows for a reduction of Fetal Bovine Serum supplementation자세히 알아보기
Have Questions?
보기 방식 변경
| 카탈로그 번호 | 수량 |
|---|---|
| 22600050 | 10 x 1 L |
| 22600134 | 10 L |
카탈로그 번호 22600050
제품 가격(KRW)
437,000
Online offer
Ends: 31-Mar-2026
485,000할인액 48,000 (10%)
Each
수량:
10 x 1 L
제품 가격(KRW)
437,000
Online offer
Ends: 31-Mar-2026
485,000할인액 48,000 (10%)
Each
Opti-MEM™ Reduced-Serum Medium is an improved Minimal Essential Medium (MEM) that allows for a reduction of Fetal Bovine Serum supplementation by at least 50% with no change to growth rate or morphology. Opti-MEM™ is also recommended for use with cationic lipid transfection reagents, such as Lipofectamine™ reagent. Opti-MEM™ can be used with a variety of suspension and adherent mammalian cells, including Sp2, AE-1, CHO, BHK-21, HEK, and primary fibroblasts. We offer a variety of Gibco™ Opti-MEM™ modifications for a range of cell culture applications.
The complete formulation is confidential. For more information, please contact Technical Services.
Gibco™ Opti-MEM™ is a unique media that contains insulin, transferrin, hypoxanthine, thymidine, and trace elements. These additional components allow for a reduction in serum supplementation by at least 50%.
Product Intended Use
For in vitro diagnostic use. CAUTION: Not for human or animal therapeutic use. Uses other than the intended use may be a violation of local law.
cGMP Manufacturing and Quality System
Gibco™ Opti-MEM™ is manufactured at a cGMP compliant facility, located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards. For supply chain continuity, we offer a comparable Gibco™ Opti-MEM™ product made in our Scotland facility (22600-134). This facility is registered with the FDA as a medical device manufacturer and is certified to the ISO 13485 standard.
Gibco™ Opti-MEM™ uses a sodium bicarbonate buffer system (2.4 g/L) and therefore requires a 5-10% CO2 environment to maintain physiological pH.
Powder forms of Gibco™ cell culture medium require sodium bicarbonate supplementation, pH adjustment and filtration at the time of preparation (see protocol for details).
This product is not used for in vitro diagnostic purpose in some countries.
This Opti-MEM™ is modified as follows:
| With |
| • L-glutamine |
| • Phenol Red |
The complete formulation is confidential. For more information, please contact Technical Services.
Gibco™ Opti-MEM™ is a unique media that contains insulin, transferrin, hypoxanthine, thymidine, and trace elements. These additional components allow for a reduction in serum supplementation by at least 50%.
Product Intended Use
For in vitro diagnostic use. CAUTION: Not for human or animal therapeutic use. Uses other than the intended use may be a violation of local law.
cGMP Manufacturing and Quality System
Gibco™ Opti-MEM™ is manufactured at a cGMP compliant facility, located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards. For supply chain continuity, we offer a comparable Gibco™ Opti-MEM™ product made in our Scotland facility (22600-134). This facility is registered with the FDA as a medical device manufacturer and is certified to the ISO 13485 standard.
Gibco™ Opti-MEM™ uses a sodium bicarbonate buffer system (2.4 g/L) and therefore requires a 5-10% CO2 environment to maintain physiological pH.
Powder forms of Gibco™ cell culture medium require sodium bicarbonate supplementation, pH adjustment and filtration at the time of preparation (see protocol for details).
This product is not used for in vitro diagnostic purpose in some countries.
Not for human or animal therapeutic use. Uses other than the intended use may be a violation of local law. For in vitro diagnostic use.
사양
세포주Sp2, AE-1, CHO, BHK-21, and HEK
세포 유형Primary Fibroblasts
제조 품질cGMP-compliant under the ISO 13485 standard
제품라인Gibco, Opti-MEM
제품 유형Opti-MEM I
수량10 x 1 L
유통 기한30 Months From Date of Manufacture
배송 조건Room Temperature
분류Animal Origin
형태Powder
멸균Sterile-filtered
첨가제 포함Glutamine, Phenol Red
Unit SizeEach
구성 및 보관
Storage conditions: 2-8° C
Shipping conditions: Ambient
Shelf life: 30 months from date of manufacture
Shipping conditions: Ambient
Shelf life: 30 months from date of manufacture
자주 묻는 질문(FAQ)
Do you offer an alternative for Opti-MEM Reduced Serum Medium powder (Cat. No. 22600050)?
How much Opti-MEM Reduced Serum Medium, powder (Cat. No. 22600050, 22600134) should I use to reconstitute the media?
Is there any other difference between Opti-MEM I Reduced Serum Medium and Opti-MEM I Reduced Serum Medium, no phenol red besides the presence/absence of phenol red?
Where can I find the osmolality for my lot of Opti-MEM I Reduced Serum Medium?
Can I aliquot and freeze Opti-MEM I Reduced Serum Medium to conserve it longer? If so, for how long can it be stored?
인용 및 참조 문헌 (6)
인용 및 참조 문헌
Abstract
Folding of the striated muscle myosin motor domain.
Journal:J Biol Chem
PubMed ID:12110670
'We have investigated the folding of the myosin motor domain using a chimera of an embryonic striated muscle myosin II motor domain fused on its COOH terminus to a thermal stable, fast folding variant of green fluorescent protein (GFP). In in vitro expression assays, the GFP domain of the chimeric
Role of the E1A Rb-binding domain in repression of the NF-kappa B-dependent defense against tumor necrosis factor-alpha.
Journal:Proc Natl Acad Sci U S A
PubMed ID:12119420
'The adenoviral E1A oncogene sensitizes mammalian cells to tumor necrosis factor-alpha (TNF-alpha), in part by repressing the nuclear factor-kappa B (NF-kappa B)-dependent defense against this cytokine. Other E1A activities involve binding to either p300/cyclic AMP response element-binding protein (CBP) or retinoblastoma (Rb)-family proteins, but the roles of E1A interactions with
Induction of bacterial lipoprotein tolerance is associated with suppression of toll-like receptor 2 expression.
Journal:J Biol Chem
PubMed ID:12133836
'Tolerance to bacterial cell wall components including lipopolysaccharide (LPS) may represent an essential regulatory mechanism during bacterial infection. Two members of the Toll-like receptor (TLR) family, TLR2 and TLR4, recognize the specific pattern of bacterial cell wall components. TLR4 has been found to be responsible for LPS tolerance. However, the
Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line.
Journal:J Virol
PubMed ID:14671129
'Hepatitis C virus (HCV) infects liver cells and its replication in other cells is incompletely defined. Human hepatoma Huh-7 cells harboring subgenomic HCV replicons were used in somatic cell fusion experiments with human embryonic kidney 293 cells as a means of examining the permissiveness of 293 cells for HCV subgenomic
c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor kappa B transactivation.
Journal:J Biol Chem
PubMed ID:12149248
Nuclear factor kappaB (NF-kappaB) plays a key role in suppression of tumor necrosis factor (TNF)-mediated apoptosis by inducing a variety of anti-apoptotic genes. Expression of c-Myc has been shown to sensitize cells to TNF-mediated apoptosis by inhibiting NF-kappaB activation. However, the precise step in the NF-kappaB signaling pathway and apoptosis